Press Releases

Press Releases

Stay updated on the latest Vistagen News and get the details about important events, public financial reports, and our product pipeline updates.

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 28, 2024-- Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management will present
Fasedienol PALISADE Phase 3 program for the acute treatment of social anxiety disorder remains on track PALISADE-3 trial initiation anticipated in 1H 2024; PALISADE-4 trial initiation anticipated in 2H 2024 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb.
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 6, 2024-- Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, today announced it will host a conference call and webcast
Preclinical data in four well-established preclinical models of pain associated with tissue inflammation and nerve injury demonstrate AV-101’s robust effects similar to gabapentin but with a better side effect profile Phase 1 data demonstrate AV-101 is well-tolerated, with no meaningful difference
Fasedienol (PH94B) PALISADE Phase 3 Program for acute treatment of social anxiety disorder (SAD) advancing to build on recent positive PALISADE-2 Phase 3 results Preparations to initiate potential fasedienol NDA-enabling Phase 3 studies in 2024 underway Itruvone (PH10) staged for potential Phase 2B
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 8, 2023-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that
Positive top-line results from fasedienol (PH94B) Phase 3 PALISADE-2 trial in social anxiety disorder (SAD) to be presented by SAD expert, Dr. Michael Liebowitz , at CNS Summit 2023 Positive results from PH80 Phase 2A study in women diagnosed with vasomotor symptoms (hot flashes) due to menopause
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 6, 2023-- Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced it
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 5, 2023-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 2, 2023-- Vistagen Therapeutics, Inc. (“Vistagen”) (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system